Peter Mac researchers have discovered a powerful new drug combination that could offer hope to children and adults with ...

In relapsing-remitting multiple sclerosis, activation of the peripheral immune system can lead to focal inflammation within the CNS. Over the past three decades, therapeutic development has been ...

This new article publication from Acta Pharmaceutica Sinica B, discusses how a CMD-OPT model enables the discovery of a potent and selective RIPK2 inhibitor as preclinical candidate for the treatment ...

Debiopharm will take over development of the PKMYT1 inhibitor and advance it in combination with its WEE1 inhibitor in the MYTHIC trial.

Initially used for blood glucose control, the medications reduce cardiovascular events and mitigate heart failure hospitalization, regardless of diabetes status.

Patients with rheumatoid arthritis treated with Janus kinase inhibitors do not demonstrate increased risks for major cardiovascular complications vs. TNF inhibitors or other biologic disease ...

DeepCure Announces DC-15442 as Development Candidate, an Oral STAT6 Inhibitor with 100% in vivo inhibition of pSTAT6 and comparable efficacy to dupilumab across disease models ...

Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma unveiled a pair of phase 3 wins for enlicitide decanoate in patients with ...

Bayer’s Vividion Therapeutics has secured the global rights from its partner Roche to the only Werner helicase inhibitor to have made it into the clinic.

NodThera Charts Obesity Future with First Patients Dosed in Phase 2 RESOLVE-1 Trial of Oral NLRP3 Inflammasome Inhibitor NT-0796 ...

On June 3, 2025, the industry's first proof-of-concept clinical validation of AI-driven drug discovery was published in Nature Medicine. Insilico Medicine and collaborators reported promising safety ...

Conclusions: Overall, dual inhibition of HER2 and VEGF without chemotherapy is a promising therapeutic strategy for patients with breast cancer, especially those with HER2-overexpressing breast cancer ...